Taking SSRI antidepressants does not increase the risk of developmental delays or autism in children, a new study reports. However, there is an increased risk for ASD and developmental delays in children whose mothers suffer from maternal psychiatric disorders.
Fetal exposure to SRI antidepressants may affect the brain activity in newborns, a new study reports.
Alteration of placental serotonin levels due to maternal depression or antidepressant use may be associated with the disruption of placental estrogen production.
Researchers critique the latest findings on serotonin's role in depression and report people should maintain their current therapies to help control their symptoms of depression.
Researchers suggest serotonin metabolism in the pineal gland could play a role in the underlying cause of depression. The findings were based on biochemical changes which were seen to be in association with improvements in depression.
A new study reports that serotonin promotes the consolidation of traumatic memories following stress events. Additionally, SSRI medications which are commonly prescribed for PTSD may make the condition worse by enhancing the effects of serotonin.
Researchers use brain wave recordings to successfully predict patient response to common antidepressants.
Researchers report administering cannabinoids soon after a traumatic event can prevent PTSD-like symptoms in rats.
The antipsychotic medication clozapine can trigger severe obsessive-compulsive symptoms (OCS) in patients. Adding aripiprazole can help manage clozapine-associated OCS.
A new study reports Zoloft, a commonly prescribed antidepressant alters brain structure differently in those who are depressed and those who aren't.
Sertraline (Zoloft), a commonly prescribed SSRI antidepressant, may not be as effective at treating depression within 6 weeks as previously thought. However, the drug is effective for treating anxiety symptoms.
SSRI antidepressants, such as Prozac and Paxil, interact with opioid medications to make them less effective at providing relief from chronic pain. Tramadol relies on activation of the CYP2D6 enzyme to control pain, but SSRIs inhibit this enzyme. Researchers suggest prescribing different classes of antidepressants which do not suppress the enzyme may benefit those in need of opioid medications. Alternatively, non-opioid pain killers should be considered for those who can not switch from SSRIs.